Abstract: The present disclosure provides a fusion molecule comprising a miRNA analog fused to a peptide via a linker for use in cosmetic skin lightening. Also provided in the disclosure are formulations comprising said fusion molecule, methods of preparation and uses thereof.
Claims:1. A fusion molecule for skin lightening, said fusion molecule comprising:
a. a RNA fragment having sequence as set forth in SEQ ID NO: 1;
b. a cross-linker having structure of Figure 1;
c. a peptide having amino acid sequence as set forth in SEQ ID NO: 2,
wherein said RNA fragment 3’ end is fused to the N-terminal end of the said peptide by said cross-linker.
2. A method of preparing a fusion molecule as claimed in claim 1.
3. A formulation for topical application comprising:
a. a fusion molecule as claimed in claim 1; and
b. suitable carriers, diluents, and excipients.
4. A method of preparing a formulation as claimed in claim 3.
5. A method of cosmetic skin lightening, said method comprising:
a. obtaining a fusion molecule as claimed in claim 1; and
b. contacting said fusion molecule with skin,
wherein said method results in skin lightening.
6. The method as claimed in claim 5, wherein said fusion molecule concentration is in the range of 5pM-100nM.
7. A method of cosmetic skin lightening, said method comprising:
a. obtaining a formulation as claimed in claim 3; and
b. contacting said formulation with skin,
wherein said method results in skin lightening.
8. The method as claimed in claim 7, wherein in said formulation, fusion molecule concentration is in the range of 5pM-100nM.
9. A fusion molecule as claimed in claim 1 for use in preparation of cosmetics for topical application to inhibit skin pigmentation.
10. A fusion molecule as claimed in claim 1 for use in inhibition of skin pigmentation.
, Description:As Attached
| # | Name | Date |
|---|---|---|
| 1 | 5681-CHE-2015-FER.pdf | 2021-10-17 |
| 1 | Sequence listing [21-10-2015(online)].pdf | 2015-10-21 |
| 2 | 5681-CHE-2015-FORM 18 [05-09-2019(online)].pdf | 2019-09-05 |
| 2 | Form 5 [21-10-2015(online)].pdf | 2015-10-21 |
| 3 | 5681-CHE-2015-Correspondence-301115.pdf | 2016-03-19 |
| 3 | Form 3 [21-10-2015(online)].pdf | 2015-10-21 |
| 4 | 5681-CHE-2015-Form 1-301115.pdf | 2016-03-19 |
| 4 | Drawing [21-10-2015(online)].pdf | 2015-10-21 |
| 5 | Description(Complete) [21-10-2015(online)].pdf | 2015-10-21 |
| 5 | 5681-CHE-2015-Power of Attorney-301115.pdf | 2016-03-19 |
| 6 | 5681-CHE-2015-Power of Attorney-301115.pdf | 2016-03-19 |
| 6 | Description(Complete) [21-10-2015(online)].pdf | 2015-10-21 |
| 7 | 5681-CHE-2015-Form 1-301115.pdf | 2016-03-19 |
| 7 | Drawing [21-10-2015(online)].pdf | 2015-10-21 |
| 8 | 5681-CHE-2015-Correspondence-301115.pdf | 2016-03-19 |
| 8 | Form 3 [21-10-2015(online)].pdf | 2015-10-21 |
| 9 | 5681-CHE-2015-FORM 18 [05-09-2019(online)].pdf | 2019-09-05 |
| 9 | Form 5 [21-10-2015(online)].pdf | 2015-10-21 |
| 10 | Sequence listing [21-10-2015(online)].pdf | 2015-10-21 |
| 10 | 5681-CHE-2015-FER.pdf | 2021-10-17 |
| 1 | patentlenssearchE_04-01-2021.pdf |
| 1 | TPOE_04-01-2021.pdf |
| 2 | patentlenssearchE_04-01-2021.pdf |
| 2 | TPOE_04-01-2021.pdf |